Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Mio Matsubara"'
Autor:
Misa Kimura, Yoichi Sakurada, Yoshiko Fukuda, Mio Matsubara, Yumi Kotoda, Yuka Kasai, Atsushi Sugiyama, Wataru Kikushima, Daphne Viel Tsuru, Kenji Kashiwagi
Publikováno v:
Pharmaceuticals, Vol 17, Iss 6, p 687 (2024)
Purpose: We compared 12-month outcomes of eyes with polypoidal choroidal vasculopathy (PCV) with or without complete regression of polyps observed one month after three monthly intravitreal administrations (loading phase) of aflibercept (2.0 mg/0.05
Externí odkaz:
https://doaj.org/article/42563a0195374928b27c42ffc46960ec
Autor:
Wataru Kikushima, Yoichi Sakurada, Atsushi Sugiyama, Seigo Yoneyama, Mio Matsubara, Yoshiko Fukuda, Taiyo Shijo, Yumi Kotoda, Serena Fragiotta, Kenji Kashiwagi
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-8 (2022)
Abstract Hyperreflective foci (HRF) are the findings observed in optical coherence tomography (OCT) in several retinal diseases and are believed to be associated with the increased risk of atrophy in eyes with age-related macular degeneration (AMD).
Externí odkaz:
https://doaj.org/article/19ca26257fdd426dba9c83b79b3994b1
Autor:
Seigo Yoneyama, Ayumi Fukui, Yoichi Sakurada, Nobuhiro Terao, Taiyo Shijo, Natsuki Kusada, Atsushi Sugiyama, Mio Matsubara, Yoshiko Fukuda, Wataru Kikushima, Ravi Parikh, Fumihiko Mabuchi, Chie Sotozono, Kenji Kashiwagi
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-8 (2022)
Abstract To investigate the differences in clinical and genetic characteristics between males and females with central serous chorioretinopathy (CSC). Consecutive 302 patients (mean age; 56.3 ± 11.7, male/female: 249/53) with CSC were evaluated on t
Externí odkaz:
https://doaj.org/article/bfb0dde9f3ca4978a018dc892df7314c
Autor:
Wataru Kikushima, Yoichi Sakurada, Yoshiko Fukuda, Mio Matsubara, Yumi Kotoda, Atsushi Sugiyama, Kenji Kashiwagi
Publikováno v:
Pharmaceuticals, Vol 16, Iss 4, p 562 (2023)
We aimed to investigate whether a treat-and-extend regimen of intravitreal brolucizumab (6.0 mg/0.05 mL) is effective for eyes with exudative age-related macular degeneration (AMD) refractory to aflibercept for 12 months. Sixty eyes from 56 patients
Externí odkaz:
https://doaj.org/article/d1dd306c8ebf421fb854d26207b8d81c
Autor:
Seigo Yoneyama, Ayumi Fukui, Yoichi Sakurada, Nobuhiro Terao, Taiyo Shijo, Natsuki Kusada, ATSUSHI Sugiyama, Mio Matsubara, Yoshiko Fukuda, Wataru Kikushima, Fumihiko Mabuchi, Chie Sotozono, Kenji Kashiwagi
Publikováno v:
Retina. 43:389-395
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ffed6c287e45fcae717ce0a244d2d84c
https://doi.org/10.1097/iae.0000000000003692
https://doi.org/10.1097/iae.0000000000003692
Autor:
Wataru Kikushima, Atsushi Sugiyama, Seigo Yoneyama, Mio Matsubara, Yoshiko Fukuda, Ravi Parikh, Yoichi Sakurada
Publikováno v:
PLoS ONE, Vol 15, Iss 3, p e0230505 (2020)
[This corrects the article DOI: 10.1371/journal.pone.0229231.].
Externí odkaz:
https://doaj.org/article/94c63f4c4b90470a814cbcdf70a40e44
Autor:
Kikushima Wataru, Atsushi Sugiyama, Seigo Yoneyama, Mio Matsubara, Yoshiko Fukuda, Ravi Parikh, Yoichi Sakurada
Publikováno v:
PLoS ONE, Vol 15, Iss 2, p e0229231 (2020)
We report 5-year visual and anatomical outcomes after combination therapy of photodynamic therapy (PDT) and intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy (PCV) and predictive factors for visual outcomes at
Externí odkaz:
https://doaj.org/article/ba7282aa40644cceb1dc1dad6521b0a2
Autor:
Mio Matsubara, Yoichi Sakurada, Atsushi Sugiyama, Yoshiko Fukuda, Ravi Parikh, Kenji Kashiwagi
Publikováno v:
PLoS ONE, Vol 15, Iss 8, p e0237330 (2020)
We investigated whether response to photodynamic therapy (PDT) with intravitreal aflibercept injection (IAI) for polypoidal choroidal vasculopathy (PCV) differs depending on fellow eye condition. A retrospective review was conducted for consecutive 6
Externí odkaz:
https://doaj.org/article/c709306a25b04bc1b89a46d26fdd2890
Autor:
Yoshiko Fukuda, Yoichi Sakurada, Mio Matsubara, Yuka Hasebe, Atsushi Sugiyama, Wataru Kikushima, Kenji Kashiwagi
Publikováno v:
Biomedicines, Vol 9, Iss 9, p 1164 (2021)
We compared the short-term outcomes between 3-monthly aflibercept and brolucizumab injections for treatment-naïve polypoidal choroidal vasculopathy (PCV). A total of 52 eyes were included. Patients received 3 monthly intravitreal aflibercept (n = 38
Externí odkaz:
https://doaj.org/article/eadc85eb8f87422eb368bf8144d21ca1
Autor:
Taiyo Shijo, Yoichi Sakurada, Seigo Yoneyama, Wataru Kikushima, Atsushi Sugiyama, Mio Matsubara, Yoshiko Fukuda, Fumihiko Mabuchi, Kenji Kashiwagi
Publikováno v:
Pharmaceuticals, Vol 13, Iss 9, p 257 (2020)
We investigated whether polygenic risk score (PRS) was associated with one-year outcome of as-needed aflibercept therapy for exudative age-related macular degeneration (AMD), including AMD (n = 129) and polypoidal choroidal vasculopathy (n = 132). A
Externí odkaz:
https://doaj.org/article/a60ad7dc2e14441ea53b665bbf8d964a